© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Few chemicals have influenced diabetes research the way streptozotocin has. Discovered from soil bacteria called Streptomyces achromogenes in the 1950s, researchers noticed it killed pancreatic beta cells in lab animals. That unique feature made it a gold standard for inducing diabetes in experimental models. Its rise wasn’t instant—not many people wanted to work with something that toxic. Early reports told of its antibiotic activity, but lab results soon had others seeing its potential for cancer chemotherapy and diabetes studies. By the 1960s, scientists everywhere started to use it in research, giving birth to thousands of studies focused on blood sugar control, pancreatic function, and the search for better diabetes treatments.
Streptozotocin now comes in various grades, from pure research material to GMP-quality product for potential clinical investigations. The powder draws a following among laboratories trying to model Type 1 diabetes. Supplied in tightly sealed vials, it’s kept cold and dry because it breaks down with light and moisture. Producers, often biotech firms or chemical supply giants, focus on consistent potency since that controls the experimental outcome. In practice, a lot hinges on batch-to-batch performance, so companies deliver robust QC data with every shipment.
The compound looks off-white or yellowish, slightly hygroscopic, and dissolves easily in water. Its molecular formula is C8H15N3O7. Some say it smells faintly sweet, though not many want to take too deep a sniff. It has a low melting point, usually under 160°C, and crystallizes as a monohydrate. Its stability depends on pH, light, and temperature—degrading fast in neutral or alkaline solutions. Researchers must work fast once it's dissolved, or risk inconsistent effects on their cells and animals.
Suppliers tend to list purity as over 98 percent, confirmed by HPLC or similar instruments. Labels carefully declare the storage recommendation—usually between minus 20 and minus 80 degrees Celsius—to ensure viability. Safety warnings are front and center. Most vials ship in quantities ranging from 25 mg up to a gram. Certificates of analysis specify appearance, purity, identification by mass spectrometry or NMR, and water content. A close look at labeling demonstrates the care around its hazardous nature.
Traditional production taps into fermentation and advanced purification. First, the actinomycete culture is grown on a rich medium, then fermentation is run for days to accumulate the compound in the broth. Extracting streptozotocin involves solvent partition and precipitation steps, usually followed by column chromatography to pull out impurities. Final crystallization delivers the powder in a stable form. Seamless technology has helped improve yields over the years, but it still remains a multi-step process involving both chemical and biological controls.
Streptozotocin is a nitrosourea compound with a glucose tail. Its nitrosourea group is highly reactive—it tends to alkylate DNA, which brings on its cell-killing effects. Researchers explore various chemical tweaks on its structure to probe for modified function or less toxicity, with some focusing on the glucose moiety to redirect uptake pathways. In the hands of medicinal chemists, it’s a scaffold for novel antitumor agents. Despite attempts, few derivatives match its specificity to target beta cells.
Known by several aliases, streptozotocin sometimes appears as STZ, Streptozocin, Zanosar, or NSC-85998. It grabs attention under trade names in chemotherapy circles, yet lab-based researchers still ask for STZ. Sometimes, technical literature sticks with the full name: N-(methylnitrosocarbamoyl)-D-glucosamine. No matter the label, pros handling the product check the chemical structure against the trusted sources to make certain they have the right stuff.
Safety with streptozotocin can’t be overstated. It’s a powerful DNA-alkylator, considered hazardous to health by major regulatory bodies. Gloves, protective eyewear, and lab coats are the rule, not the exception. Operations take place under chemical hoods. Waste needs strict disposal methods, not regular trash bins. Training for anyone handling the powder runs deep—one slip, and the risks include respiratory, skin, and eye irritation, as well as long-term carcinogenic potential. Institutions reinforce guidelines and regularly audit compliance to minimize accidental exposure.
Most of the world knows streptozotocin as the chemical that helps scientists create Type 1 diabetes in rodents. Its use extends further, especially in cancer research as an agent for chemotherapy of certain pancreatic neuroendocrine tumors. Some studies aim to model neurological or kidney disease, using STZ to trigger specific types of tissue damage. Drug screening platforms rely on its capacity to reproducibly create a “disease state” in lab animals, offering a test bed for treatments attempting to reverse high blood sugar or stop tumor growth. The breadth of its reach means STZ has played a backbone role in diabetes understanding, islet transplantation, insulin therapy, and even immunological questions.
Interest hasn’t waned, even after decades. Researchers continue to seek better animal models of diabetes, and for many, STZ-induced models remain a favorite thanks to their reliability. Development of less toxic analogs, or agents with fewer off-target effects, moves forward in chemistry labs worldwide. In parallel, advanced analytical methods help clarify exactly how STZ damages beta cells, offering clues about both the roots of diabetes and possible new ways to protect pancreatic function. Pharmaceutical companies engage in structural exploration, while academic teams keep testing new administration protocols, dosing regimens, and synergistic treatments.
Toxicity stands at the core of all STZ work. It isn’t subtle—administered in the wrong dose or under unproven protocols, and outcomes get unpredictable or lethal to test subjects. Decades of documentation show varying sensitivities among animal species and even between strains within species. Chronic exposure at even low levels leads to cumulative DNA damage and cancer risk. Researchers now pay extra attention to the transient versus chronic disease phases after dosing: the compound destroys islet cells, but also has bystander effects elsewhere. Toxicity studies also sharpen risk evaluations for lab teams, dictating the care with which trials or experiments proceed.
Some may ask whether future advances might push streptozotocin out of its current prominence. Excitement surrounds technologies like CRISPR or stem-cell based beta cell destruction, but they haven’t fully replaced the reliability of chemical methods in routine labs. The quest for safer, more precise animal models carries on. New derivatives are being developed to narrow target specificity or limit systemic exposure. Environmental and occupational health experts set their sights on less hazardous alternatives, and global shifts in animal research ethics could eventually alter STZ’s central place in diabetes research. For now, its unique chemistry secures its spot, but new discoveries and stricter regulations could reshape how scientists build and test the next generation of diabetes therapies.
Streptozotocin started out as an antibiotic found in soil bacteria, but its story took some twists and turns. Instead of ending up as a regular infection-fighter, this compound landed in research labs and oncologists’ toolkits. Most folks who know it well work in medical research or treat certain types of cancer.
Doctors may pick streptozotocin for patients with rare cancers called pancreatic neuroendocrine tumors. These tumors don’t behave like most ordinary pancreatic cancers. They’re so stubborn, common chemotherapy drugs bounce off them like rubber balls. What sets streptozotocin apart is its unique ability to slip inside these particular cancer cells and disrupt their DNA, stopping tumors from growing. While it doesn’t give a cure for everyone, it makes a difference for some, especially folks for whom other options have run dry. Published results from clinical trials and the National Cancer Institute both reflect modest but real response rates, often giving patients precious extra months or years.
I remember talking with a diabetes researcher who explained how streptozotocin shapes our understanding of blood sugar problems. In labs around the world, scientists depend on this compound to bring on diabetes in animals. Streptozotocin wipes out insulin-making beta cells in the pancreas. With these cells gone, mice and rats start to look a lot like people with type 1 diabetes: their blood sugar skyrockets, and they show all the familiar symptoms. This may sound odd—giving a drug just to make animals sick—but without this process, we’d be years behind in figuring out how diabetes works or testing which new insulin therapies might work for people.
Some folks worry about animal research, and there’s plenty of discussion about finding models that skip this step. Still, most breakthroughs in transplanting beta cells, testing new drugs, and tweaking insulin pumps have relied on these experiments. As long as research teams keep tightening their ethical standards and look for alternatives, animal testing stays important, especially for diseases we can’t study any other way.
On the clinical side, dealing with streptozotocin isn’t for the faint-hearted. The drug has some serious baggage—lots of patients run into nausea, vomiting, and kidney trouble. Doctors monitor kidney function before every dose, and people receiving this treatment almost always get special hydration plans. Based on my time working at a cancer clinic, the conversations before starting this kind of chemo are always honest and detailed. Nobody pretends it comes without risk, but for some, the potential payoff justifies it.
Streptozotocin’s story doesn’t end with the lab or the chemo infusion room. Every year, researchers come up with new discoveries about the way it damages cell DNA, hoping to invent more targeted therapies with fewer side effects. The ultimate hope isn’t just to treat rare tumors or model diabetes in rats—it's about understanding disease processes so deeply that new treatments won’t need to be nearly so harsh.
Addressing old-fashioned chemical risks often points toward smarter drug design, tighter rules in research, and open conversations with patients. For now, this tricky compound keeps making an impact, nudging medicine forward both at the bedside and in the science journals.
Streptozotocin stands out in the world of scientific research, especially for those studying diabetes. It comes from a soil bacterium called Streptomyces achromogenes. Scientists noticed this compound fits well into diabetes studies after they saw what it does inside a living body. Streptozotocin targets cells in the pancreas, more specifically the beta cells—the body’s engine for producing insulin. By damaging these cells, the chemical helps researchers simulate diabetes in laboratory animals, especially rats and mice, so they can develop and test better treatments.
Human biology relies on the pancreas making enough insulin to keep blood sugar balanced. Streptozotocin sneaks into pancreatic beta cells through a protein called the GLUT2 transporter. Beta cells, more than any other cells, open their “doors” wide to this chemical. Once inside, streptozotocin damages the cell’s DNA and pushes the cell toward death. No elaborate mechanisms here: DNA breaks apart, cellular processes derail, and the cell stops working. The immune system then clears out the dead cells. With beta cells gone, insulin plummets and blood sugar rises, giving scientists a close mimic of type 1 diabetes.
I remember the first time I saw a lab rat receive streptozotocin. The changes were swift. Blood sugar shot up, appetite faded, and fur turned rough. These effects are not just numbers on a chart. They echo the real-life pain of people who rely on insulin shots every day. Researchers have relied on this model for decades. Without it, modern insulin pumps, glucose meters, and routine therapies might have taken much longer to hit the market. Data shows that since the 1960s, streptozotocin has appeared in tens of thousands of published studies touching everything from immunology to renal failure. It gets the job done, although it can cause problems beyond pancreatic damage—liver and kidney toxicity sometimes complicate experiments and mean researchers need to use caution.
This compound brings hope for better diabetes treatments, but it’s no friend to the human body outside a tightly-controlled experiment. Because of its toxicity, strict protocols control its use. Researchers measure doses to minimize suffering in lab animals and make the model as reliable as possible. Still, there is no way to completely dodge risk. Any handling or exposure can damage kidneys, liver or other organs, both in animals and humans who might accidentally contact the compound. Safety goggles, gloves, and biosafety hoods become part of daily life in labs where it’s in use.
There’s growing interest in lowering dependence on animal models like those created with streptozotocin. Scientists are developing 3D cell cultures and organ-on-chip models with human cells to predict real-world drug effects more directly. These tools might someday take the lead in diabetes research, but for now, streptozotocin shapes much of what we know about the disease. Careful oversight and ongoing research into safer, more human-relevant tools remain key to progress. For everyone affected by diabetes, these efforts hold the promise of treatments with fewer side effects, delivered with more precision.
Streptozotocin started as an antibiotic and later turned into a chemotherapy drug, mostly used for rare pancreatic tumors and in laboratory diabetes research. While it plays a key role in medicine and science, most folks rarely hear about it unless cancer or diabetes is part of their story. My own brush with its reputation came during volunteer work at a university diabetes research lab, where I learned just how sensitive living systems can be to small changes. That sensitivity becomes painfully clear when talking about the fallout from this drug’s use.
A wave of nausea and vomiting shows up for almost everybody taking Streptozotocin. Folks often report stomach pain or loss of appetite, which can lead to weight loss if treatments keep going. Fevers and chills sometimes follow, and fatigue becomes routine. It doesn’t surprise anyone who has spent time in a hospital chemo ward; toxic agents hit more than just cancer cells.
The kidneys take a direct hit. Streptozotocin is what doctors call nephrotoxic. I’ve met people who needed weekly bloodwork after treatment started, just to keep track of rising creatinine levels. If doctors miss early signs, kidney function can drop fast, leading to more hospital time, specialist visits, and intense worry for both patients and families.
Long-lasting issues sometimes crop up. Rough on insulin-producing cells, the drug can leave people with new-onset high blood sugar—much like the diabetes it’s used to study in lab animals. Blood sugar spikes are more than a nuisance. I once met a survivor who now needs daily insulin because of pancreatic damage from chemotherapy, which changed her approach to daily meals and travel for the rest of her life.
Some people wind up with liver trouble, because the drug moves through there as well. Blood tests may show enzyme changes, and jaundice isn’t off the table. Doctors keep an eye on the liver and usually make quick medication adjustments, but that brings stress and tough conversations about whether to stick with treatment.
Doctors lean into monitoring. Kidney and liver function often gets checked before every round of Streptozotocin, so problems get caught sooner. Anti-nausea medication becomes a routine prescription. Common sense—good hydration, frequent lab tests, and education—plays a big role. Nurses often spend a lot of time setting expectations for side effects and offering reassurance that someone will listen if new symptoms pop up.
Other options, like splitting doses or choosing different meds altogether, sometimes provide a safer path for people with underlying risk factors. Clinical teams try to balance disease control with life quality—never an easy task.
Information makes a difference. People facing a diagnosis want to know the risks because it shapes treatment choices and daily routines. My own takeaway from talking with patients and researchers: open, honest conversations can lighten the emotional load. Involving caregivers and family in every step gives everyone a better shot at staying on top of warning signs—and finding ways to make tough days just a little bit easier.
Streptozotocin’s side effects may be daunting, but they gain context and manageability when health professionals, patients, and families work as a team. Staying informed helps keep surprises to a minimum, which can mean more control in an otherwise unpredictable situation.
Streptozotocin pops up often in research labs focused on diabetes, respected for its ability to wipe out insulin-producing beta cells in the pancreas. You usually see this compound prepared as a fresh solution right before it enters the animal subject. Researchers reach for a sterile saline or Citrate buffer to dissolve the powder. Once dissolved, there’s no waiting around—this compound breaks down quickly, forcing a tight window for action.
Most labs deliver Streptozotocin through an injection into the peritoneal cavity—called intraperitoneal injection. The skin is pinched, a small needle goes in at an angle, and the solution enters the space around the abdominal organs. Others stick with intravenous injection, pushing the solution straight into a vein, often in the tail for rodents. Some researchers report that the method changes the depth of diabetes symptoms, and intravenous tends to hit the system with a quick, hard punch.
Streptozotocin isn’t gentle. It can wreck more than just pancreas cells. It’s toxic to the kidneys and can trigger nausea or sudden drops in blood sugar. Researchers watch their subjects closely, sometimes with glucose on hand to fend off sharp drops in blood sugar. They keep injection volumes as low as possible. Dosing works out to milligrams per kilogram of body weight, with labs double-checking every calculation. Even with experience and published protocols, mistakes happen, so constant vigilance matters.
Streptozotocin can harm humans if it touches skin or gets inhaled. I remember spending years in labs where compounds like this demanded full protective gear. Gloves, masks, gowns, and eye protection became non-negotiable. Fumes get handled in a chemical hood. Every surface or tool that touches the compound gets decontaminated or disposed of as hazardous waste. Accidents draw swift, serious responses. Even a splash gets treated as an emergency, with immediate washing and medical reporting.
Researchers aim for reproducibility. They shape injection details based on animal age, weight, and health. Protocols published in journals become bibles in the lab. Experienced staff train newcomers shoulder-to-shoulder. These habits protect not just the animals but also the scientists, and ensure experiments can be repeated in other labs. Ethical committees demand rigorous accountability before any injection starts—and with reason.
Streptozotocin has driven decades of diabetes study. Still, questions linger about animal suffering and alternatives that could cut down on animal use. Some teams experiment with lower doses across several days to ease the shock to the animals’ systems. Others test protective drugs or pre-treatments to reduce unintended harm. Every tweak requires careful tracking, data collection, and honest reporting.
No two labs prepare or deliver Streptozotocin in exactly the same way, just as no batch of animals responds identically. This is where the experience from past runs shapes present decisions. Old timers know which animals struggle and how to spot early warning signs of distress. They build on peer-reviewed methods and keep up with guidelines from expert groups like the American Association for Laboratory Animal Science (AALAS).
Safe, accurate Streptozotocin administration keeps research moving and animals protected. It isn’t glamorous, but it’s where science and animal care overlap—grounded in experience, sharpened by attention to detail, and guided by respect for the living beings involved.
Streptozotocin shows up in medicine mostly as a treatment for certain cancers, especially rare ones like pancreatic neuroendocrine tumors. This drug works by damaging cells, especially those in the pancreas, and doctors turn to it when other options run short. While it can help save lives, it brings a heavy load of risks. Knowing who should stay away from it can make a real difference.
People with kidney disease should think twice about Streptozotocin. This drug leaves the body through the kidneys. If those aren’t working well, the medicine can build up to dangerous levels. Research from the Journal of Clinical Oncology points out that people with less than normal kidney function run into trouble much faster. It rarely makes sense to put this group on a drug that puts extra pressure on their kidneys. Doctors usually seek another option or reduce the dose carefully, but even that may not spare these patients from real harm.
The liver handles stress from chemotherapy drugs every day. Streptozotocin can push a stressed liver over the edge. People living with cirrhosis, chronic hepatitis, or other liver problems might end up in the hospital with liver failure if they take this chemotherapy. Few people realize that even a mild liver setback can turn deadly fast during cancer treatment. The American Cancer Society warns that regular liver checks during treatment are non-negotiable. Frequent blood tests to track liver function tend to spot trouble early, but avoiding the drug altogether in these cases seems like a safer bet.
Doctors often use Streptozotocin in the lab to mimic diabetes in animals. The reason? It destroys insulin-making cells. If someone with diabetes or even close to developing it starts this drug, blood sugar can spin out of control. With my own family’s struggles with diabetes, I’ve seen firsthand how even small changes in medication or stress levels can send blood sugar into chaos. Adding Streptozotocin stacks the odds against anyone trying to keep their glucose stable. Even for those without a clear diagnosis, doctors check fasting blood sugar carefully before writing a prescription.
Pregnancy brings its own complexities. Medications that may harm a developing baby rarely get approval for use during pregnancy. Streptozotocin ranks among those flagged as extremely risky. Studies in animals show birth defects and lost pregnancies at high rates after taking this drug. The National Institutes of Health strongly warns pregnant folks to avoid this medication unless no other options exist. Those breastfeeding face a similar dilemma, since the drug can pass into breast milk and hurt a newborn’s developing cells. Conversations about safer cancer treatments during pregnancy or breastfeeding usually end with a clear “not this one.”
On rare occasions, folks can have a severe allergic reaction. Signs like swelling, itching, trouble breathing, or a sudden drop in blood pressure demand quick action. For people with a past reaction to any cancer drug, doctors proceed with real caution. Personal experience tells me that most people tend to brush off the risk of allergies, but chemotherapy drugs have a history of provoking some of the worst reactions in medicine.
Anyone facing a Streptozotocin prescription deserves a straight talk with their doctor. Blood work, scans, and careful review of medical history should all come before that first dose. Newer drugs and clinical trials sometimes open other doors. The main takeaway: not every treatment fits every person, and a cancer diagnosis doesn’t mean accepting unnecessary risks from a mismatched drug.
| Names | |
| Preferred IUPAC name | 2-deoxy-2-({[(methylnitrosoamino)carbonyl]amino}-D-glucopyranose) |
| Other names |
Streptozocin STZ Zanosar |
| Pronunciation | /strɛpˌtoʊzoʊtəˈsiːn/ |
| Identifiers | |
| CAS Number | 18883-66-4 |
| Beilstein Reference | 120787 |
| ChEBI | CHEBI:9525 |
| ChEMBL | CHEMBL1090 |
| ChemSpider | 21105582 |
| DrugBank | DB00628 |
| ECHA InfoCard | 100.024.516 |
| EC Number | 3.2.2.18 |
| Gmelin Reference | 1091318 |
| KEGG | C00424 |
| MeSH | D013290 |
| PubChem CID | 29327 |
| RTECS number | XZ2230000 |
| UNII | YS09L6US2Y |
| UN number | UN1851 |
| Properties | |
| Chemical formula | C8H15N3O7 |
| Molar mass | 265.219 g/mol |
| Appearance | White to pale yellow powder |
| Odor | Odorless |
| Density | 1.32 g/cm³ |
| Solubility in water | Soluble in water |
| log P | -3.4 |
| Acidity (pKa) | 12.03 |
| Basicity (pKb) | 9.62 |
| Magnetic susceptibility (χ) | -36.2e-6 cm^3/mol |
| Refractive index (nD) | 1.69 |
| Viscosity | Viscous liquid |
| Dipole moment | 7.61 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | Std molar entropy (S⦵298) of Streptozotocin: 381.8 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | Std enthalpy of combustion (ΔcH⦵298) of Streptozotocin: -3595 kJ/mol |
| Pharmacology | |
| ATC code | A10AX04 |
| Hazards | |
| Main hazards | May cause cancer, may damage fertility or the unborn child, causes damage to organs (pancreas), harmful if swallowed, causes serious eye irritation, may cause respiratory irritation. |
| GHS labelling | GHS02, GHS06, GHS08 |
| Pictograms | GHS06, GHS08 |
| Signal word | Danger |
| Hazard statements | H300 + H310 + H330, H350 |
| Precautionary statements | P201, P202, P260, P264, P270, P272, P280, P281, P302+P352, P308+P313, P314, P362+P364, P405, P501 |
| NFPA 704 (fire diamond) | Health: 3, Flammability: 1, Instability: 2, Special: - (NFPA 704) |
| Autoignition temperature | Autoignition temperature: 410°C |
| Lethal dose or concentration | LD50 rat oral 110 mg/kg |
| LD50 (median dose) | 210 mg/kg (rat, intravenous) |
| NIOSH | MI4800000 |
| PEL (Permissible) | PEL: "0.1 mg/m³ (Skin) |
| REL (Recommended) | 150 mg/m² every 7 days |
| IDLH (Immediate danger) | Unknown |
| Related compounds | |
| Related compounds |
Methyl nitrosourea Zanosar N-Nitroso compounds |
